| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
25,230,000 |
| Market
Cap: |
298.98(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.8 - $14.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verastem is a late stage development biopharmaceutical company, with ongoing registration directed trials, focused on developing and commercializing medicines for patients battling cancer. Co.'s product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors. VS-6766 is an orally available small molecule rapidly accelerated fibrosarcoma/ mitogen-activated protein kinase kinase clamp. Defactinib is an oral small molecule inhibitor of Focal Adhesion Kinase and proline-rich tyrosine kinase that is being evaluated as a potential combination therapy for various solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,735 |
21,833 |
25,311 |
165,018 |
| Total Sell Value |
$18,442 |
$258,319 |
$292,764 |
$385,800 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
9 |
20 |
37 |
63 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Westphal Christoph H |
Executive Chairman |
• • – |
2015-06-30 |
4 |
D |
$6.86 |
$18,165 |
D/D |
(2,648) |
665,224 |
|
- |
|
| Singh Monica |
General Counsel |
• – – |
2015-06-29 |
4 |
B |
$6.95 |
$6,950 |
D/D |
1,000 |
2,000 |
2.74 |
- |
|
| Green John B |
Chief Financial Officer |
• – – |
2015-06-29 |
4 |
B |
$7.12 |
$3,560 |
D/D |
500 |
2,500 |
2.66 |
- |
|
| Forrester Robert |
President and CEO |
• • – |
2015-06-29 |
4 |
B |
$7.11 |
$14,210 |
D/D |
2,000 |
226,924 |
2.81 |
- |
|
| Green John B |
Chief Financial Officer |
• – – |
2015-06-26 |
4 |
B |
$7.39 |
$3,696 |
D/D |
500 |
2,000 |
2.66 |
- |
|
| Paterson Dan |
Chief Operating Officer |
• – – |
2015-06-18 |
4 |
B |
$8.05 |
$8,045 |
D/D |
1,000 |
32,571 |
2.74 |
- |
|
| Forrester Robert |
President and CEO |
• • – |
2015-06-17 |
4 |
B |
$7.97 |
$7,970 |
D/D |
1,000 |
224,924 |
2.81 |
- |
|
| Westphal Christoph H |
Executive Chairman |
• • – |
2015-03-31 |
4 |
D |
$10.49 |
$29,550 |
D/D |
(2,817) |
674,328 |
|
- |
|
| Kauffman Michael |
Director |
– • – |
2015-03-19 |
4 |
S |
$10.96 |
$10,192 |
D/D |
(930) |
2,070 |
|
- |
|
| Paterson Dan |
Chief Operating Officer |
• – – |
2015-02-01 |
4 |
D |
$7.30 |
$46,100 |
D/D |
(6,315) |
31,571 |
|
- |
|
| Forrester Robert |
President and CEO |
• • – |
2015-02-01 |
4 |
D |
$7.30 |
$59,787 |
D/D |
(8,190) |
223,924 |
|
- |
|
| Barberich Timothy J |
Director |
– • – |
2015-01-28 |
4 |
B |
$6.50 |
$250,003 |
D/D |
38,462 |
39,462 |
2.39 |
- |
|
| Westphal Christoph H |
Executive Chairman |
• • – |
2015-01-28 |
4 |
B |
$6.50 |
$7,999,999 |
I/I |
1,230,769 |
1,230,769 |
2.66 |
- |
|
| Westphal Christoph H |
Executive Chairman |
• • – |
2015-01-08 |
4 |
D |
$9.19 |
$53,394 |
D/D |
(5,810) |
683,601 |
|
- |
|
| Westphal Christoph H |
Executive Chairman |
• • – |
2015-01-08 |
4 |
A |
$0.00 |
$0 |
D/D |
11,622 |
689,411 |
|
- |
|
| Westphal Christoph H |
Executive Chairman |
• • – |
2014-12-31 |
4 |
D |
$8.86 |
$24,542 |
D/D |
(2,770) |
677,789 |
|
- |
|
| Phanstiel S. Louise |
Director |
– • – |
2014-12-29 |
4 |
B |
$8.54 |
$85,435 |
I/I |
10,000 |
26,500 |
2.1 |
- |
|
| Horobin Joanna |
Chief Medical Officer |
• – – |
2014-12-29 |
4 |
B |
$8.60 |
$6,450 |
D/D |
750 |
750 |
2.74 |
- |
|
| Sherwin Stephen A |
Director |
– • – |
2014-12-26 |
4 |
B |
$8.56 |
$21,395 |
I/I |
2,500 |
2,500 |
2.1 |
- |
|
| Friedman Paul A |
Director |
– • – |
2014-12-24 |
4 |
B |
$8.31 |
$24,932 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| Termeer Henri A |
Director |
– • – |
2014-12-23 |
4/A |
B |
$8.11 |
$113,509 |
I/I |
14,000 |
14,000 |
2.1 |
- |
|
| Termeer Henri A |
Director |
– • – |
2014-12-23 |
4/A |
B |
$8.11 |
$121,625 |
D/D |
15,000 |
32,179 |
2.39 |
- |
|
| Termeer Henri A |
Director |
– • – |
2014-12-23 |
4 |
B |
$8.09 |
$81,747 |
I/I |
10,100 |
10,100 |
2.1 |
- |
|
| Termeer Henri A |
Director |
– • – |
2014-12-23 |
4 |
B |
$8.09 |
$72,799 |
D/D |
9,000 |
27,079 |
2.39 |
- |
|
| Green John B |
Chief Financial Officer |
• – – |
2014-12-23 |
4 |
B |
$8.17 |
$4,085 |
D/D |
500 |
1,500 |
2.66 |
- |
|
168 Records found
|
|
Page 6 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.07 (0.59%) 
